Literature DB >> 17453339

Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L).

Natalya V Guseva1, Oskar W Rokhlin, Agshin F Taghiyev, Michael B Cohen.   

Abstract

The majority of breast cancer cell lines are resistant to tumor necrosis factor -related apoptosis inducing ligand (TRAIL) induced apoptosis. TRAIL and Fas receptor death-inducing signaling complex (DISCs) formation are similar and involve ligand-dependent recruitment of FADD and caspase-8. We have found that the breast carcinoma cell line T47D is an unusual example of selective sensitivity to anti-Fas mAb treatment but resistant to TRAIL. Therefore, a detailed comparison of these two signaling pathways in one cell line should provide insight into the mechanism of TRAIL resistance. We observed that only anti-Fas mAb induces caspase activation and cell death in T47D. Further, FADD and caspase-8 interact with both TRAIL-R1 and TRAIL-R2, and that the amount of caspase-8 recruited by Fas-, TRAIL-R1 and TRAIL-R2 are the same. cFLIP(S) and cFLIP(R )isoforms block death receptor-induced apoptosis by inhibiting caspase-8 activation at the DISC; the role of cFLIP(L )at the DISC is still controversial. It has been suggested that the presence of the cleaved form of FLIP(L)-p43 at the DISC prevents caspase-8 cleavage. We found that both TRAIL and anti-Fas mAb-induced DISCs contain the cleaved form of p43 cFLIP(L) and its amount at the Fas DISC was higher compared to the TRAIL DISC. We also found that inhibition of cFLIP(L) expression in T47D cells decreased Fas-mediated caspase-8 activation and activation of effector caspases. We propose that in T47D p43 cFLIP(L) in the Fas-DISC may promote caspase-8 activation. The mechanism by which different amounts of p43cFLIP(L) regulates caspase-8 activation remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17453339     DOI: 10.1007/s10549-007-9563-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  11 in total

1.  WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis.

Authors:  Sireesha V Garimella; Andrea Rocca; Stanley Lipkowitz
Journal:  Mol Cancer Res       Date:  2011-11-23       Impact factor: 5.852

2.  Combination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA.

Authors:  Robert Riehle; Bhushan Pattni; Aditi Jhaveri; Abhijit Kulkarni; Ganesh Thakur; Alexei Degterev; Vladimir Torchilin
Journal:  Pharm Res       Date:  2016-03-07       Impact factor: 4.200

3.  Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL.

Authors:  Alena Vaculova; Vitaliy Kaminskyy; Elham Jalalvand; Olga Surova; Boris Zhivotovsky
Journal:  Mol Cancer       Date:  2010-04-23       Impact factor: 27.401

4.  Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model.

Authors:  Manonmani Ganapathy; Rita Ghosh; Xie Jianping; Xiaoping Zhang; Roble Bedolla; John Schoolfield; I-Tien Yeh; Dean A Troyer; Aria F Olumi; Addanki P Kumar
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

Review 5.  The TRAIL to targeted therapy of breast cancer.

Authors:  Monzur Rahman; Janet G Pumphrey; Stanley Lipkowitz
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

6.  Death Receptors: New Opportunities in Cancer Therapy.

Authors:  V M Ukrainskaya; A V Stepanov; I S Glagoleva; V D Knorre; A A Jr Belogurov; A G Gabibov
Journal:  Acta Naturae       Date:  2017 Jul-Sep       Impact factor: 1.845

7.  Vital function of PRELI and essential requirement of its LEA motif.

Authors:  M R McKeller; S Herrera-Rodriguez; W Ma; B Ortiz-Quintero; R Rangel; C Candé; J C Sims-Mourtada; V Melnikova; C Kashi; L M Phan; Z Chen; P Huang; K Dunner; G Kroemer; K K Singh; H Martinez-Valdez
Journal:  Cell Death Dis       Date:  2010       Impact factor: 8.469

Review 8.  Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges.

Authors:  Ehsan Razeghian; Wanich Suksatan; Heshu Sulaiman Rahman; Dmitry O Bokov; Walid Kamal Abdelbasset; Ali Hassanzadeh; Faroogh Marofi; Mahboubeh Yazdanifar; Mostafa Jarahian
Journal:  Front Immunol       Date:  2021-08-20       Impact factor: 7.561

9.  MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.

Authors:  Andrea Turner; Liang-Cheng Li; Tania Pilli; Lixia Qian; Elizabeth Louise Wiley; Suman Setty; Konstantin Christov; Lakshmy Ganesh; Ajay V Maker; Peifeng Li; Prasad Kanteti; Tapas K Das Gupta; Bellur S Prabhakar
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

Review 10.  Onto better TRAILs for cancer treatment.

Authors:  D de Miguel; J Lemke; A Anel; H Walczak; L Martinez-Lostao
Journal:  Cell Death Differ       Date:  2016-03-04       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.